All AbMole products are for research use only, cannot be used for human consumption.
AU-15330 is a protein hydrolysis-targeted chimeric (PROTAC) degradation of SWI/SNF ATPase subunits SMARCA2 and SMARCA4, and also induces effective tumor growth inhibition in a prostate cancer xenograft model.
| Cell Experiment | |
|---|---|
| Cell lines | VCaP cells |
| Preparation method | VCaP cells were treated with DMSO for 24 h or AU-15330 (1 μM) for increasing time durations. |
| Concentrations | 1 μM |
| Incubation time | 24 h |
| Animal Experiment | |
|---|---|
| Animal models | Castrated male mice bearing the VCaP-CRPC xenografts |
| Formulation | AU-15330 was added in 40% of 2-hydroxypropyl-β-cyclodextrin (HPβCD) and sonicated until completely dissolved, and then the solution was further mixed with 5% dextrose in water (D5W) to reach a final concentration of 10% HPβCD. |
| Dosages | 10, 30 mg/kg |
| Administration | Intravenous injection |
| Molecular Weight | 755.94 |
| Formula | C39H49N9O5S |
| CAS Number | 2380274-50-8 |
| Form | Solid |
| Solubility (25°C) | DMSO >140 mg/mL |
| Storage | 4°C, dry |
[2] Lanbo Xiao, et al. Nature. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
| Related PROTAC Products |
|---|
| CR8
CR8 is a potent and selective inhibitor of cyclin dependent kinase (CDK1, 2, 5, 7, and 9). |
| ARV-393
ARV-393 is an orally active PROTAC degrader targeting BCL6 for studies related to diffuse large B-cell lymphoma. ARV-393 utilizes the ubiquitin-proteasome system to target the degradation of BCL6. |
| ARV-766
ARV-766 is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations. ARV-766 has the potential to be first- and best-in class PROTAC AR degrader in mCRPC. |
| Indisulam
Indisulam is a carbonic anhydrase inibitor and antitumor CDK inhibitor. Indisulam targets the G1 phase of the cell cycle by depleting cyclin E. inducing p53 and p21, and inhibiting CDK2, causing a blockade in the G1/S transition. |
| dBET6
dBET6 is a highly potent, selective and cell-permeable PROTAC connected by ligands for Cereblon and BET, with an IC50 of 14 nM, and has antitumor activity. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
